Home

The law firms of Charney Lawyers PC and Rice Harbut Elliott LLP have commenced a national class action on behalf of all persons resident in Canada who ingested and/or were prescribed and/or purchased one or more contaminated Metformin products on the recall list set out below.

For more information about registering with the law firm to receive updates on the class actions and to help us collect information for use in the class actions, please click here.

We recommend that you do not throw away any leftover Metformin pills. If possible, store them in a safe place for potential testing and proof of purchase.

Health Canada detects NDMA in Metformin products

An impurity, N-nitrosodimethylamine (NDMA), has been detected in some Metformin products for sale in Canada. NDMA is a potential human carcinogen, which means that it could cause cancer with long-term exposure.

The active pharmaceutical ingredient Metformin is indicated for the treatment of high blood sugar in patients with type 2 diabetes. Metformin products are available in Canada by prescription.

On December 5, 2019, Health Canada issued a product information update advising that they are evaluating the presence of NDMA in some Metformin drugs.

A further Health Canada report on February 5, 2020, advised that Apotex Inc., one of the leading manufacturers of Metformin, was recalling certain lots of the diabetes medication APO-Metformin ER (extended release) 500mg tablets.

A further Health Canada report on February 26, 2020, advised that Ranbaxy Pharmaceuticals Canada Inc. was recalling six lots of its prescription RAN-Metformin drug from the Canadian market. Company testing identified two lots (#AJY8006A and #AJY8007A) with levels of NDMA above what is considered acceptable if the drug were to be taken over a lifetime. Health Canada also stated that Ranbaxy Pharmaceuticals Canada Inc. was recalling an additional four lots (#AJY8005A, #AJY8005B, #AJY8008A and #AJZ8005A) as a precautionary measure because they contain NDMA close to the acceptable limit.

A further Health Canada report on March 11, 2020, advised that JAMP Pharma Corporation was voluntarily recalling all 26 lots of its prescription Metformin drug from the Canadian market (Metformin DIN 02380196 [500mg] and Metformin DIN 02380218 [850mg]) as a precautionary measure. Although NDMA test results were not available for this product; the recall has been initiated because of the potential presence of nitrosamine impurities in the finished product.

A further Health Canada report on June 12, 2020, advised that Apotex Inc. was voluntarily recalling 9 lots of its prescription Metformin drug from the Canadian market (Metformin DIN 02305062 [500mg]) because lot PY7174 contained NDMA that increased over time to a level above the acceptable limit. As a precautionary measure, Apotex Inc. is recalling the eight other lots because levels of NDMA in those products may increase over time.

Recalls and safety alerts from Health Canada

Health Canada evaluating NDMA in metformin drugs, Health Canada, (updated December 5, 2019)
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71831a-eng.php

APO-Metformin (2020-02-04), Health Canada (updated February 4, 2020)
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72281r-eng.php

Ranbaxy Metformin Product Recall (2020-02-26), Health Canada (updated February 27, 2020)
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72455r-eng.php

Certain Metformin diabetes drugs recalled due to the presence or possible presence of NDMA, Health Canada (updated June 13, 2020)
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72287a-eng.php"

Jamp-Metformin Product Recall (2020-03-10), Health Canada (updated March 12, 2020)
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72565r-eng.php

APO-Metformin (2020-06-12), Health Canada (updated June 13, 2020)
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/73339r-eng.php#affected-touches

Health Canada’s list of Metformin products being recalled in Canada at this time:

(Copied directly from Health Canada’s website)

Company Product Name/Active Pharmaceutical Ingredient (API) DIN Strength Lot Expiry
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg NV3242 04/2020
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg NV3244 04/2020
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg NV3245 04/2020
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg NV3243 04/2020
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg NV3247 04/2020
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg NV3248 04/2020
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg PX5334 01/2021
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg PX5335 01/2021
Ranbaxy Pharmaceuticals Canada Inc. RAN-Metformin 02269031 500mg AJY8006A 05/2020
Ranbaxy Pharmaceuticals Canada Inc. RAN-Metformin 02269031 500mg AJY8007A 05/2020
Ranbaxy Pharmaceuticals Canada Inc. RAN-Metformin 02269031 500mg AJY8005A 05/2020
Ranbaxy Pharmaceuticals Canada Inc. RAN-Metformin 02269031 500mg AJY8005B 05/2020
Ranbaxy Pharmaceuticals Canada Inc. RAN-Metformin 02269031 500mg AJY8008A 05/2020
Ranbaxy Pharmaceuticals Canada Inc. RAN-Metformin 02269031 850mg AJZ8005A 05/2020
JAMP Pharma Metformin 02380196 500mg X20283 11/2020
JAMP Pharma Metformin 02380196 500mg X20284 11/2020
JAMP Pharma Metformin 02380196 500mg X20286 11/2020
JAMP Pharma Metformin 02380196 500mg X20287 11/2020
JAMP Pharma Metformin 02380196 500mg X20288 11/2020
JAMP Pharma Metformin 02380196 500mg Y00225 12/2020
JAMP Pharma Metformin 02380196 500mg Y00226 12/2020
JAMP Pharma Metformin 02380196 500mg Y00227 12/2020
JAMP Pharma Metformin 02380196 500mg Y00228 01/2021
JAMP Pharma Metformin 02380196 500mg Y00229 01/2021
JAMP Pharma Metformin 02380196 500mg Y00230 01/2021
JAMP Pharma Metformin 02380196 500mg Y00231 05/2021
JAMP Pharma Metformin 02380196 500mg Y00232 05/2021
JAMP Pharma Metformin 02380196 500mg Y01573 05/2021
JAMP Pharma Metformin 02380196 500mg Y01574 05/2021
JAMP Pharma Metformin 02380196 500mg Y01575 05/2021
JAMP Pharma Metformin 02380196 500mg Y01576 05/2021
JAMP Pharma Metformin 02380196 500mg Y01577 05/2021
JAMP Pharma Metformin 02380196 500mg Y01578 05/2021
JAMP Pharma Metformin 02380196 500mg Y01579 06/2021
JAMP Pharma Metformin 02380196 500mg Y01580 06/2021
JAMP Pharma Metformin 02380218 850mg X20385 07/2020
JAMP Pharma Metformin 02380218 850mg X20386 07/2020
JAMP Pharma Metformin 02380218 850mg X19224 10/2020
JAMP Pharma Metformin 02380218 850mg X19225 10/2020
JAMP Pharma Metformin 02380218 850mg X19226 10/2020
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg PK3968 09/2020
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg PK3969 09/2020
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg PX5336 01/2021
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg PY7174 02/2021
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg PY7175 01/2021
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg RF6463 06/2021
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg RF6464 06/2021
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg RF6465 06/2021
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500mg RF6466 06/2021